| Trial ID: | L4907 |
| Source ID: | NCT02372955
|
| Associated Drug: |
Dapagliflozin
|
| Title: |
Mechanistic Study of the Systolic Blood Pressure Lowering Effect of Dapagliflozin in Type 2 Diabetes
|
| Acronym: |
|
| Status: |
UNKNOWN
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes Mellitus Type 2
|
| Interventions: |
DRUG: dapagliflozin|DRUG: glimpiride
|
| Outcome Measures: |
Primary: systolic blood pressure by ambulatory blood pressure monitoring (ABPM), 16 weeks|arterial stiffness, arterial stiffness will be assessed by measuring aortic pulse wave velocity (aPWV) and augmentation index, 16 weeks | Secondary: urinary sodium excretion, 16 weeks|composite intravascular volume status, jugular venous pressure, body weight, orthostatic change in BP and pulse rate, 16 weeks
|
| Sponsor/Collaborators: |
Sponsor: Gulf Regional Research & Educational Services, LLC
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
21
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT
|
| Start Date: |
2015-02
|
| Completion Date: |
2016-12
|
| Results First Posted: |
|
| Last Update Posted: |
2015-02-26
|
| Locations: |
Gulf Regional Research & Educational Services, LLC, Metairie, Louisiana, 70002, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT02372955
|
